BioSpace News Archive

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, today announced that preclinical data on its TurboCAR™ technology will be presented in a poster session at the virtual American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting on May 12, 2020.

Dr. Sandra Schmid has been named as the first Chief Scientific Officer at the Chan Zuckerberg Biohub, a nonprofit research organization setting the standard for collaborative science, where leaders in science and technology come together to drive discovery and support the bold vision, to cure, prevent or manage disease in our children’s lifetime.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track Designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today the pricing of an underwritten public offering of 11,630,000 ordinary shares

Prokarium is pleased to announce it has signed an exclusive, worldwide Option Agreement with the Lausanne University Hospital - CHUV, a Switzerland-based research hospital, to acquire a license to cover the treatment of Non-Muscle Invasive Bladder Cancer patients with intravesical instillations of Salmonella.

US Pharma (Zubsolv® US) net revenues of SEK 163.9 m (161.7), up 1.3 percent in SEK and -4.0 percent in local currency. HQ & Pipeline net revenues of SEK 11.1 m (12.6).

Australian life sciences company, QBiotics Group Limited has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event.

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, announced that the cash payments of Board fees will be suspended and replaced with Immuron stock.

Invivoscribe, Inc., a global leader in the development and commercialization of precision diagnostics announced that they will begin offering coronavirus COVID-19 testing through their CLIA/CAP, NY State Licensed LabPMM reference laboratory in San Diego, CA.

Electromedical Technologies, Inc., a pioneer in the development and manufacturing of bioelectronic devices, including the WellnessPro®, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to provide a forecast for expected first quarter performance for 2020.